New pill aimed at Hard-to-Treat GVHD enters early human testing
Disease control
Recruiting now
This early-phase trial tests an oral drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of effectiveness. All participants have mo…
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC